Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.

Atai Life Sciences, a clinical-stage biopharmaceutical company focused on mental health treatments, announced the completion of a public offering on February 14, 2025, raising approximately $63.25 ...

atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies ...

An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming ...

atai is enrolling patients into Elumina, the Phase 2, multi-center, double-blind, randomized, placebo-controlled, trial to assess the efficacy, safety and tolerability of VLS-01 in people ...

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinical development of short ...